A randomized, open label study to evaluate the renal safety of Bondronat [ibandronic acid] infusions over 15 minutes or 60 minutes in patients with metastatic bone disease due to breast cancer.

Trial Profile

A randomized, open label study to evaluate the renal safety of Bondronat [ibandronic acid] infusions over 15 minutes or 60 minutes in patients with metastatic bone disease due to breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 08 Dec 2008 Status changed from active, no longer recruiting to completed.
    • 09 Jan 2008 Status changed from recruiting to in progress.
    • 02 Aug 2007 Results have been reported (at the 43rd Annual Meeting of the American Society of Clinical Oncology)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top